Manufactures, sells and exports chemicals, drugs and fertilizers

Part of Alkermes Plc, Alkermes Controlled Therapeutics, Inc. is a company headquartered in the United States specializing in pharmaceutical preparations.

Alkermes Pharma Ireland Ltd., part of Alkermes Plc, is a company headquartered in Athlone, Ireland. The firm develops and manufactures oral dosage products.

Techsphere SA de CV is a Mexican private company, with operations in MX, that manufactures pharmaceutical products.

Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland.

Dyckerhoff AG engages in the production of cement and ready-mixed concrete products. Its products include dray cement, white cement, and concrete. The company was founded by Wilhelm Gustav Dyckerhoff, Gustav Dyckerhoff, and Rudolf Dyckerhoff on June 4, 1864 and is headquartered in Wiesbaden, Germany.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Bracco International BV wholesales and distributes pharmaceutical products. It engages in the promotion and marketing of products manufactured by Bracco SpA across the world. The company was founded in 1991 and is headquartered in Amsterdam, the Netherlands.

Asarina Pharma AB is a Swedish biotech company focusing on the development of Sepranolone (UC1010) for the treatment of premenstrual dysphoric disorder and other menstrually related conditions. The company's primary goal is to offer a novel therapy that is specifically designed for PMDD. Asarina has a second generation oral compound in preclinical development for PMDD

BioSphere Medical SA designs and manufactures medical devices for radiological treatments. The company is headquartered in Roissy, France.

Part of Bracco SpA, Bracco Suisse SA is a company headquartered in Manno, Switzerland, that engages in pharmaceutical research and development.

May & Baker Ltd. manufactures pharmaceutical products. The company is headquartered in Guildford, GB.

Roussel UCLAF.

Dimerix Bioscience is a public unlisted clinical stage drug discovery and development company, and a wholly owned subsidiary of Sun Biomedical Limited (ASX:SBN Sun Biomedical Home Page). Based in Melbourne, Dimerix’s lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200. This study has repurposing of existing molecules at its core, and upon successful results from this study, Dimerix intends to pursue the pathway of registration of a product for an orphan indication. The study has been initiated at the Austin Hospital under the supervision of Professor Power, and is currently recruiting patients. The therapeutic rationale for DMX-200 was developed from Dimerix’s core patented technology, known as Receptor – Heteromer Investigation Technology (Receptor – HIT) which can be used to elucidate receptor interactions. Applying this technology to receptors such as G-protein coupled receptors (GPCR’s), Dimerix is able to identify differences in signaling behavior when receptors interact as heteromers, as expected in vivo, compared with the traditional analysis of single target receptors in isolation. In recent years Dimerix has been approached by several top 10 Pharmaceutical companies, and has assisted these with their drug discovery programs by applying the HIT technology and in house knowledge. These studies have assisted in validating Dimerix’s in vitro approach as a rationale for pursuing in vivo therapeutic studies.

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Tepha is a medical device firm pursuing the development and commercialization of innovative products based on the company's proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates , which may be tailored to meet unmet needs for medical devices in multiple fields. Tepha's novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention.

Bauer Spezialtiefbau GmbH, part of Bauer AG, is a German company located in Schrobenhausen that provides construction services. Arnulf Christa and Frank Haehnig are the current co-CEOs of the firm.